全文获取类型
收费全文 | 1884659篇 |
免费 | 135625篇 |
国内免费 | 4100篇 |
专业分类
耳鼻咽喉 | 24361篇 |
儿科学 | 61556篇 |
妇产科学 | 50153篇 |
基础医学 | 268761篇 |
口腔科学 | 53046篇 |
临床医学 | 166760篇 |
内科学 | 375119篇 |
皮肤病学 | 43673篇 |
神经病学 | 148670篇 |
特种医学 | 69670篇 |
外国民族医学 | 331篇 |
外科学 | 281175篇 |
综合类 | 39743篇 |
现状与发展 | 4篇 |
一般理论 | 590篇 |
预防医学 | 141998篇 |
眼科学 | 44003篇 |
药学 | 137297篇 |
7篇 | |
中国医学 | 5000篇 |
肿瘤学 | 112467篇 |
出版年
2021年 | 15628篇 |
2019年 | 16685篇 |
2018年 | 25990篇 |
2017年 | 19191篇 |
2016年 | 20600篇 |
2015年 | 23390篇 |
2014年 | 30832篇 |
2013年 | 45518篇 |
2012年 | 66172篇 |
2011年 | 68784篇 |
2010年 | 39323篇 |
2009年 | 35629篇 |
2008年 | 63039篇 |
2007年 | 67129篇 |
2006年 | 66720篇 |
2005年 | 63889篇 |
2004年 | 61371篇 |
2003年 | 57926篇 |
2002年 | 55652篇 |
2001年 | 96197篇 |
2000年 | 98125篇 |
1999年 | 81017篇 |
1998年 | 20429篇 |
1997年 | 17881篇 |
1996年 | 17963篇 |
1995年 | 17254篇 |
1994年 | 15756篇 |
1993年 | 14477篇 |
1992年 | 59830篇 |
1991年 | 57516篇 |
1990年 | 55083篇 |
1989年 | 52679篇 |
1988年 | 48066篇 |
1987年 | 46744篇 |
1986年 | 43924篇 |
1985年 | 41517篇 |
1984年 | 30506篇 |
1983年 | 25881篇 |
1982年 | 14472篇 |
1979年 | 26544篇 |
1978年 | 18295篇 |
1977年 | 15574篇 |
1976年 | 14413篇 |
1975年 | 15248篇 |
1974年 | 18492篇 |
1973年 | 17810篇 |
1972年 | 16471篇 |
1971年 | 15261篇 |
1970年 | 14182篇 |
1969年 | 13310篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
12.
13.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
14.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
15.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献
16.
17.
Clinical & Experimental Metastasis - 相似文献
18.
19.
20.
Barouyr Baroudjian Dimitri Arangalage Stefania Cuzzubbo Baptiste Hervier Celeste Lebbé Gwenael Lorillon 《Expert review of anticancer therapy》2019,19(3):209-222
Introduction: Immune checkpoint inhibitors (ICI) are now a standard of care in the treatment of many cancers leading to durable responses in patients with metastatic disease. These agents are generally well tolerated but may lead to the occurrence of immune-related adverse events (irAEs). As any organ may be affected, clinicians should be aware of the broad range of clinical manifestations and symptoms and keep in mind that toxicities may occur late, at any point along a patient’s treatment course. Although the most common irAEs are rarely severe, some of them may be associated with great morbidity and even become life-threatening. The rate of occurrence, type and severity of irAEs may vary with the type of ICI; thus, grade 3 and 4 irAEs are reported in more than 55% of patients treated with the combination of ipilimumab 3 mg/kg and nivolumab 1 mg/kg.
Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs.
Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices. 相似文献